ArticleMolecular biology reports2025
Exploring the therapeutic potential of nutraceutical compounds (Curcumin, Quercetin, Epa, Zinc, and Vitamin D) in managing Celiac disease: insights from cellular mechanisms.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Rethinking Celiac Disease Management: Treatment Approaches Beyond the Gluten-Free Diet.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe primary treatment for Celiac disease (CeD) is a gluten-free diet (GFD), which presents challenges. Studies on the anti-inflammatory properties of Curcumin, Quercetin, Vitamin D, Zinc, and Eicosapentaenoic acid (EPA) offer hope for patients. This study evaluated their effects on immune reactivity in gliadin-stimulated Caco-2 cells. METHODS AND
resultsCells were treated with pepsin trypsin-digested gliadin (PT-G) and exposed to these compounds individually and in combinations using the n-1 method. Gene expressions of TNF-α, NF-κB, STAT-3, ZO-1, and Occludin were analyzed via qPCR, while IL-6 and IL-10 protein levels were measured using ELISA. Results showed a significant decrease in NF-κB gene expression for Curcumin (P < 0.01), Quercetin (P < 0.001), Vitamin D (P < 0.01), Zinc (P < 0.01), EPA (P < 0.001), and CQEDZ (P < 0.05). IL-6 levels increased significantly with Curcumin (P < 0.05), EPA (P < 0.01), Vitamin D (P < 0.05), and Zinc (P < 0.05), along with EDZ (P < 0.0001) and DZ (P < 0.01). IL-10 levels also rose following treatments with Curcumin (P < 0.05) and Zinc (P < 0.01). ZO-1 gene expression increased with EPA (P < 0.0001), Curcumin (P < 0.0001), Quercetin (P < 0.05), and Vitamin D (P < 0.01), while it decreased in CQEDZ (P < 0.01) and other combinations.
conclusionsFindings suggest that nutraceuticals, particularly CQEDZ, CEDZ, EDZ, and ED, may modulate inflammatory pathways in CeD. Further mechanistic and clinical studies are needed to validate these results, supporting the potential of nutraceuticals in managing CeD.
Indexed as
Identifiers
40498343What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.